Budesonide capsules for IgA kidney disease
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a special steroid capsule called budesonide can help treat IgA nephropathy, a kidney disease where your immune system damages the kidneys. You would take this medication along with standard care to see if it slows kidney damage and reduces protein in your urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- At least 18 years old
- Kidney biopsy in the past 2 weeks showing IgA nephropathy (primary type only)
- Kidney function not too low (eGFR ≥ 20)
- Protein in urine between 0.5–3.5 grams per day
- No recent or ongoing infections like hepatitis, TB, or HIV
- Willing to take budesonide capsules plus standard supportive care
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
This trial tests a new medicine (FXS6837) for people with IgA nephropathy (a kidney disease that causes protein in the urine and can lead to kidney damage). The goal is to see if it can reduce protein loss and protect kidney function.
This trial tests a personalized approach that uses a blood test to help guide targeted therapies for IgA nephropathy and IgA vasculitis. It may help reduce kidney damage and control the disease with fewer side effects.
This study tests a new medicine called FXS6837 for people with IgA nephropathy, a kidney disease. It is a long-term follow-up for people who already finished a previous study with this medicine, to see if it keeps working safely over time.
This study tests a new drug, MY008211A, for people with a type of kidney disease called IgA nephropathy. The goal is to see if it can reduce protein in the urine and help protect kidney function. You must have had a kidney biopsy confirming the diagnosis and be on stable standard care.
This trial tests starting a special form of budesonide (Nefecon) early in people with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and protect kidney function.
Hear when a new IgA Glomerulonephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.